Claims for Patent: 5,990,176

Summary for Patent: 5,990,176

Title:	Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
Abstract:	The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
Inventor(s):	Bieniarz; Christopher (Highland Park, IL), Chang; Steve H. (Gurnee, IL), Cromack; Keith R. (Lake Bluff, IL), Huang; Shuyen L. (Riverwoods, IL), Kawai; Toshikazu (Tsurugashima, JP), Kobayashi; Manami (Miyoshimachi, JP), Loffredo; David (Elmhurst, IL), Raghavan; Rajagopalan (Grayslake, IL), Speicher; Earl R. (Buffalo Grove, IL), Stelmach; Honorate A. (Lake Forest, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL) Central Glass Company Ltd. (Tokyo, JP)
Application Number:	08/789,679
Patent Claims:	1. An anesthetic composition comprising: a quantity of sevoflurane; and a Lewis acid inhibitor in an amount effective to prevent degradation by a Lewis acid of said quantity of sevoflurane, said Lewis acid inhibitor selected from the group consisting of water, butylated hydroxytoluene, methylparaben, propylparaben, propofol, and thymol. 2. The composition of claim 1 wherein the Lewis acid inhibitor is water. 3. The composition of claim 2 containing at least about 0.04% w/w to about 0.14% w/w of water. 4. A method of preparing the anesthetic composition of claim 1 comprising the step of adding the Lewis acid inhibitor to said quantity of sevoflurane. 5. A method of preparing the anesthetic composition of claim 1 comprising the step of adding said quantity of sevoflurane, to the Lewis acid inhibitor. 6. A method of preventing degradation by a Lewis acid of a quantity of sevoflurane, the method comprising the steps of: providing a quantity of sevoflurane; providing a Lewis acid inhibitor in an amount sufficient to prevent degradation by a Lewis acid of said quantity of sevoflurane, said Lewis acid inhibitor selected from the group consisting of water, butylated hydroxytoluene, methylparaben, propylparaben, propofol, and thymol; combining said quantity of sevoflurane and the Lewis acid inhibitor in an amount sufficient to prevent the degradation by a Lewis acid of said quantity of sevoflurane. 7. The method of claim 6 wherein the Lewis acid inhibitor is water. 8. The method of claim 2 wherein the amount of water added to the sevoflurane is from about 0.04% w/w to about 0.14% w/w. 9. An anesthetic composition comprising: a quantity of sevoflurane; and water in an amount effective to prevent degradation by a Lewis acid of said quantity of sevoflurane. 10. A method of preventing degradation by a Lewis acid of a quantity of sevoflurane, the method comprising the steps of: providing a quantity of sevoflurane; providing water in an amount sufficient to prevent degradation by a Lewis acid of said quantity of sevoflurane; combining said quantity of sevoflurane and said water in an amount sufficient to prevent the degradation by a Lewis acid of said quantity of sevoflurane.